Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-11-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司子公司拟开展融资租赁业务并由公司、公司董事长暨实际控制人提供关联担保的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion issued by CITIC Securities regarding a financing lease business proposed by subsidiaries of Shenzhen BGI Co., Ltd. It discusses the provision of related-party guarantees by the company and its chairman, who is also the actual controller. The document includes detailed descriptions of the transaction, parties involved, financial data of the subsidiaries, the nature of the guarantee, and the internal approval process including board and independent directors' opinions. It is a formal verification and opinion report related to a financing and guarantee transaction, not a financial report, earnings release, or regulatory announcement. The document is not a report publication announcement since it contains substantive content and is not merely announcing a report. It is not a management report or earnings release as it focuses on a specific financing transaction and related guarantees. The document fits best under Capital/Financing Update (CAP) as it provides an update on financing activities and related guarantees by the company and its chairman for subsidiaries' financing lease business.
2019-11-19 Chinese
第二届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions from the 13th meeting of the 2nd Board of Directors of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and voting results on financing lease business and the calling of an extraordinary general meeting. The content focuses on board decisions and governance matters, including independent directors' opinions and related party guarantees. There are no financial statements or detailed financial performance data presented. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a notice of dividend, capital change, or merger activity. The document fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and related governance decisions.
2019-11-19 Chinese
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary obtaining medical device registration certificates for two software products. It includes details about the registration certificates, product descriptions, and the potential impact on the company's business. The document is relatively short (1744 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or detailed management report. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-11-15 Chinese
关于参与投资的产业投资基金完成私募投资基金备案的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen BGI Co., Ltd. regarding the completion of private equity fund registration for an investment fund in which the company participates. It details the investment fund's registration, legal compliance, and fund-raising progress. The document is short (1247 characters) and serves as an update on financing/investment activity rather than a full financial report or detailed analysis. It does not contain financial statements or detailed financial data. The content fits best under Capital/Financing Update (CAP) as it relates to the company's investment and fund registration progress.
2019-11-08 Chinese
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary obtaining a medical device registration certificate for a non-small cell lung cancer mutation gene analysis software. It includes details about the registration certificate, product description, and the impact on the company. The document is short (1499 characters) and serves as a formal disclosure of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a Regulatory Filing (RNS) as a general regulatory announcement about a significant company event that does not fit other specific categories like financial reports, management changes, or capital updates.
2019-10-30 Chinese
第二届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 2nd Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on specific agenda items such as approval of the 2019 Q3 report and a related party transaction involving a subsidiary. The document does not contain the full quarterly report itself but references that the full 2019 Q3 report was published elsewhere. The document is short (1815 characters) and serves as a meeting resolution announcement rather than a full financial report or detailed management discussion. It also includes approval of a related party transaction, which is typical content for a board or supervisory board meeting announcement. Therefore, the document fits best under Board/Management Information (MANG) as it announces decisions made by the supervisory board, including approval of financial reports and corporate transactions.
2019-10-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.